PMID- 33228783
OWN - NLM
STAT- MEDLINE
DCOM- 20210803
LR  - 20210803
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 39
IP  - 1
DP  - 2020 Nov 23
TI  - Monocyte Chemoattractant Protein-1 promotes cancer cell migration via 
      c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma.
PG  - 254
LID - 10.1186/s13046-020-01756-y [doi]
LID - 254
AB  - BACKGROUND: Osteosarcoma is generally reported among younger individuals and has 
      a very poor prognosis, particularly for the development of metastasis. However, 
      more effective metastatic biomarkers and therapeutic methods are absent. Monocyte 
      chemoattractant protein-1 (MCP-1) is involved in cancer progression and 
      inflammatory recruitment. Although previous studies have reported higher serum 
      MCP-1 levels in patients with osteosarcoma, the role of MCP-1 in osteosarcoma 
      progression remains to be addressed. METHODS: The osteosarcoma cell migratory 
      ability was assessed by transwell migration assay. The MCP-1 and MMP-9 expression 
      levels were analyzed by Western blot and qPCR. The signal activation was 
      conducted by Western blot. The in vivo mouse experiment and tumor tissue array 
      were performed to confirm our findings in vitro. RESULTS: The present study 
      demonstrates that MCP-1 regulates cell mobility through matrix metalloproteinase 
      (MMP)-9 expression in osteosarcoma cells. Moreover, MCP-1 promotes MMP-9 
      expression, cell migration, and cell invasion by mediating CCR2, c-Raf, MAPK, and 
      AP-1 signal transduction. Using MCP-1 knockdown stable cell lines, we found that 
      MCP-1 knockdown reduces MMP-9 expression and cell mobility. Finally, we found 
      high MCP-1 expression levels in osteosarcoma specimens. CONCLUSIONS: Our results 
      provide prognostic value of MCP-1 in osteosarcoma by promoting MMP-9 expression.
FAU - Liu, Ju-Fang
AU  - Liu JF
AD  - School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, 
      Taipei, 110, Taiwan.
FAU - Chen, Po-Chun
AU  - Chen PC
AD  - Department of Medical Research, China Medical University Hospital, China Medical 
      University, Taichung, 40447, Taiwan.
AD  - Translational medicine center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei City, 
      11101, Taiwan.
AD  - Department of Biotechnology, College of Medical and Health Science, Asia 
      University, Taichung, 41354, Taiwan.
FAU - Chang, Tsung-Ming
AU  - Chang TM
AD  - School of Medicine, Institute of Physiology, National Yang-Ming University, 
      Taipei City, 11221, Taiwan.
FAU - Hou, Chun-Han
AU  - Hou CH
AD  - Department of Orthopedic Surgery, National Taiwan University Hospital, 100, NO. 
      1, Jen-Ai Road, Taipei City, 11102, Taiwan, ROC. chhou@ntu.edu.tw.
LA  - eng
PT  - Journal Article
DEP - 20201123
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Transcription Factor AP-1)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-raf)
RN  - EC 2.7.11.1 (Raf1 protein, human)
RN  - EC 2.7.11.24 (MAPK1 protein, human)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Animals
MH  - Bone Neoplasms/*metabolism/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/physiology
MH  - Cell Proliferation/physiology
MH  - Chemokine CCL2/*metabolism
MH  - HEK293 Cells
MH  - Heterografts
MH  - Humans
MH  - MAP Kinase Signaling System
MH  - Male
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - Mice
MH  - Mice, SCID
MH  - Mitogen-Activated Protein Kinase 1/*metabolism
MH  - Osteosarcoma/*metabolism/pathology
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-raf/*metabolism
MH  - Transcription Factor AP-1/*metabolism
MH  - Transfection
PMC - PMC7684958
OTO - NOTNLM
OT  - MCP-1
OT  - MMP-9
OT  - Migration
OT  - Osteosarcoma
COIS- The authors state no conflict of interest.
EDAT- 2020/11/25 06:00
MHDA- 2021/08/04 06:00
PMCR- 2020/11/23
CRDT- 2020/11/24 05:39
PHST- 2020/06/05 00:00 [received]
PHST- 2020/10/30 00:00 [accepted]
PHST- 2020/11/24 05:39 [entrez]
PHST- 2020/11/25 06:00 [pubmed]
PHST- 2021/08/04 06:00 [medline]
PHST- 2020/11/23 00:00 [pmc-release]
AID - 10.1186/s13046-020-01756-y [pii]
AID - 1756 [pii]
AID - 10.1186/s13046-020-01756-y [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2020 Nov 23;39(1):254. doi: 10.1186/s13046-020-01756-y.